B-2D, a brain receptor targeted by ketamine. Using cryo-EM, they visualize how ketamine binds to the receptor, controlling ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Scientists think ketamine relieves depression and anxiety by altering GluN1-2B-2D’s movements, but the effects can vary ...

New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic.

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

many questions remain regarding how ketamine affects the brain," says Furukawa. "It's been suggested for over a decade that the drug blocks a specific kind of NMDA receptor (NMDAR), called GluN1 ...

which was further reduced when ketamine was administered in combination with naloxone, but not with NMDA, thus highlighting the activity of the NMDA receptor system. In addition, morphine was also ...

MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...